Commercial-stage health care, pharmaceutical and medical technology investor, 1315 Capital LLC, closed a growth equity fund at more than $300 million, surpassing its target of $250 million. The fund, 1315 Capital II, is the firm's second fund after a 2016 closing, and was financed by endowment, foundation, family office partners, and public and private pension. Read More
